Join Growin Stock Community!

Alx oncology holdings inc.ALXO.US Overview

US StockHealthcare
(No presentation for ALXO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ALXO AI Insights

ALXO Overall Performance

ALXO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ALXO Recent Performance

-1.42%

Alx oncology holdings inc.

-3.61%

Avg of Sector

-2.16%

S&P500

ALXO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ALXO Key Information

ALXO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ALXO Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Price of ALXO

ALXO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ALXO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
5906.24
PB Ratio
6.88
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
5906.24
PB Ratio
6.88
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ALXO's latest earnings report released?

    The most recent financial report for Alx oncology holdings inc. (ALXO) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ALXO's short-term business performance and financial health. For the latest updates on ALXO's earnings releases, visit this page regularly.

  • How much cash does ALXO have?

    At the end of the period, Alx oncology holdings inc. (ALXO) held Total Cash and Cash Equivalents of 23.44M, accounting for 0.28 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ALXO's EPS continuing to grow?

    According to the past four quarterly reports, Alx oncology holdings inc. (ALXO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.42. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ALXO?

    Alx oncology holdings inc. (ALXO)'s Free Cash Flow (FCF) for the period is -17.15M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 32.81% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ALXO?

    The latest valuation data shows Alx oncology holdings inc. (ALXO) has a Price-To-Earnings (PE) ratio of -0.67 and a Price/Earnings-To-Growth (PEG) ratio of -0.28. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.